A Double-blind, Randomized, 2-period, Placebo-controlled, Single-center, Crossover Study to Assess the Therapeutic Equivalence of the EMLA Current Reference Patch and the EMLA Test Patch in Healthy Subjects.

Trial Profile

A Double-blind, Randomized, 2-period, Placebo-controlled, Single-center, Crossover Study to Assess the Therapeutic Equivalence of the EMLA Current Reference Patch and the EMLA Test Patch in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Lidocaine/prilocaine (Primary)
  • Indications Pain
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 13 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 03 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 31 Oct 2017 Planned End Date changed from 24 Nov 2017 to 5 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top